<DOC>
	<DOCNO>NCT00966875</DOCNO>
	<brief_summary>The primary purpose study help answer follow research question , provide treatment Rheumatoid Arthritis ( RA ) : - The safety LY2439821 side effect might associate . - Whether LY2439821 help participant active RA . - How much LY2439821 give participant .</brief_summary>
	<brief_title>A Study Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Study I1F-MC-RHAK multicenter study participant active RA concomitant conventional DMARD therapy . The study Phase 2 study 2 part . Part A randomized , double-blind , placebo-controlled , parallel-group , dose-ranging design Part B optional , open-label extension design . Two participant population evaluate study : bDMARD-naive participant TNFα-IR participant . Participants Part A receive multiple subcutaneous injection LY2439821 [ bDMARD-naive participant : 0 ( placebo ) , 3 , 10 , 30 , 80 , 180 mg ; TNFα-IR participant : 0 ( placebo ) , 80 180 mg ] Weeks 0 , 1 , 2 , 4 , 6 , 8 , 10 . Participants Part B receive subcutaneous injection LY2439821 160 mg Weeks 16 , 18 , 20 , every 4 week thereafter Week 60 . Participants complete Part A B total study participation approximately 72 84 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>You must age 18 75 You must active RA Qualifications Specific bDMARDnaive Population : You must regularly use methotrexate ( MTX ) least 12 week participation study Qualifications Specific TNFαIR Population : You must treat least 1 biologic TNFα inhibitor therapy either insufficient response least 3 month treatment OR intolerant treatment You must regularly use least 1 conventional DMARD stable treatment regimen You concomitantly use nonsteroidal antiinflammatory drug ( NSAIDS ) , unless stable dose within last 2 week You woman lactate breast feeding You donate 300 milliliter ( mL ) blood within last month You receive glucocorticoid administered intraarticular , intramuscular , intravenous injection oral corticosteroid average daily dose great 10 mg per day prednisone equivalent within last 4 week You surgery joint assess study within 2 month study enrollment , require study You another serious disorder illness You suffer serious bacterial infection ( example , pneumonia , cellulitis , bone joint infection ) within last 3 month You history uncontrolled high blood pressure You clinical laboratory test result entry outside normal reference range You employee clinic immediate family member employee clinic . Immediate family member define spouse , parent , child , sibling , whether biological legally adopt You currently participate discontinue within last 30 day another clinical trial involve investigational drug If woman could become pregnant study , must talk study doctor birth control use avoid get pregnant study . If postmenopausal woman , must least 45 year age menstruate last 12 month If postmenopausal woman 40 45 year age , test negative pregnancy , menstruate last 12 month , must additional blood test see participate . If male , must agree reduce risk female partner become pregnant study . Exclusions Specific bDMARDnaive Population : You receive prior bDMARD therapy TNFα , Interleukin ( IL ) 1 , IL6 , Tcell , Bcell target therapy You inadequate response minimum 3 month treatment 5 conventional DMARDs [ leflunomide , azathioprine , cyclosporine , etcetera ( etc . ) ] You use DMARDs MTX , hydroxychloroquine , sulfasalazine within last 8 week You use leflunomide within last 12 week receive cholestyramine speed elimination leflunomide body . Exclusions Specific TNFαIR Population : You currently use recently use bDMARD biologic TNFα inhibitor therapy within specify period You serious reaction biologic DMARDs , study doctor 's opinion , put serious risk You use cyclosporine immunosuppressive 8 week participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>RA</keyword>
</DOC>